AbbVie Deutschland GmbH & Co. KG
🇩🇪Germany
Clinical Trials
1.7k
Active:1533
Completed:46
Trial Phases
5 Phases
Phase 1:1470
Phase 2:23
Phase 3:39
+2 more phases
Drug Approvals
89
CIMA_AEMPS:48
EMA:19
NMPA:17
+2 more agencies
Drug Approvals
Bimatoprost Ophthalmic Solution
- Product Name
- 卢美根
- Approval Number
- 国药准字HJ20150484
- Approval Date
- Feb 17, 2025
NMPA
Adalimumab Solution for Injection
- Product Name
- 修美乐
- Approval Number
- 国药准字SJ20200007
- Approval Date
- Jan 7, 2025
NMPA
Adalimumab Solution for Injection
- Product Name
- 修美乐
- Approval Number
- 国药准字SJ20191006
- Approval Date
- Sep 2, 2024
NMPA
Bimatoprost and Timolol Maleate Eye Drops
- Product Name
- 贝美素噻吗洛尔滴眼液
- Approval Number
- 国药准字HJ20130453
- Approval Date
- Dec 11, 2023
NMPA
Upadacitinib Sustained-release Tablets
- Product Name
- 瑞福
- Approval Number
- 国药准字HJ20233125
- Approval Date
- Feb 14, 2023
NMPA
Lopinavir and Ritonavir Tablets
- Product Name
- 克力芝
- Approval Number
- 国药准字HJ20181115
- Approval Date
- Nov 16, 2022
NMPA
Dexamethasone Intravitreal Implant
- Product Name
- 傲迪适
- Approval Number
- 国药准字HJ20170377
- Approval Date
- Aug 5, 2022
NMPA
Upadacitinib Sustained-release Tablets
- Product Name
- 瑞福
- Approval Number
- 国药准字HJ20220011
- Approval Date
- Feb 18, 2022
NMPA
Upadacitinib Sustained-release Tablets
- Product Name
- 瑞福
- Approval Number
- 国药准字HJ20220010
- Approval Date
- Feb 18, 2022
NMPA
Lopinavir and Ritonavir Tablets
- Product Name
- 克力芝
- Approval Number
- 国药准字HJ20170213
- Approval Date
- Dec 20, 2021
NMPA
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (1538 trials with phase data)• Click on a phase to view related trials
Phase 1
1470 (95.6%)Phase 3
39 (2.5%)Phase 2
23 (1.5%)phase_1_2
3 (0.2%)phase_2_3
1 (0.1%)Not Applicable
1 (0.1%)Phase 4
1 (0.1%)No trials found
News
No news found